All sponsors

4D Molecular Therapeutics $FDMT

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-33
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO71%

Delay Index: of 7 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →

Open 4D Molecular Therapeutics on the live radar map → 📅 $FDMT readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
4D-310
NCT04519749
P1/2Active, not recruitingFabry Disease182026-01
4D-125 IVT Injection
NCT04517149
P1/2Active, not recruitingX-Linked Retinitis Pigmentosa212026-06 (+39 mo)
4D-310
NCT05629559
P1/2RecruitingFabry Disease182026-06 (+24 mo)
4D-150 IVT
NCT05197270
P1/2RecruitingNeovascular (Wet) Age-Related Macular Degeneration2152027-03 (+9 mo)
4D-150 IVT (3E10 vg/eye)
NCT06864988
P3Active, not recruitingMacular Neovascularization Secondary to Age-Related Macular Degeneration4802027-06
CF
NCT05248230
P2RecruitingCystic Fibrosis Lung302027-06 (+34 mo)
4FRONT-2
NCT07064759
P3RecruitingNeovascular Age-Related Macular Degeneration (nAMD)4802027-11 (-12 mo)
4SIGHT
NCT07867080
P3RecruitingDiabetic Macular Edema (DME)5142029-01
4D-150 IVT
NCT05930561
P2Active, not recruitingDiabetic Macular Edema; Diabetic Retinopathy722029-02-28 (+12 mo)